Discovery of Phosphatidylinositol 3-Kinase Inhibitory Compounds from the Screening Committee of Anticancer Drugs (SCADS) Library
スポンサーリンク
概要
- 論文の詳細を見る
Identification of new uses for existing drugs is known to be an efficient approach in drug discovery. The identification of a novel phosphatidylinositol 3-kinase (PI3K) inhibitor is important in terms of cancer chemotherapy because PI3K is implicated in many types of cancer. In an effort to discover new PI3K inhibitory compounds, we recently carried out a screening of Screening Committee of Anticancer Drugs (SCADS) library, a compound library mainly composed of antitumor drugs and kinase inhibitors. As a result, six new PI3K inhibitory compounds were identified each of which displayed over 60% inhibition of PI3Kα at 10 μM. Baicalein, the most potent of these inhibitors, exhibited 73% inhibition at 1 μM. Further characterization of Baicalein and Akt inhibitor VIII showed that both compounds displayed comparable inhibition against PI3Kβ and δ, but relatively weak activity against PI3Kγ. Growth inhibition effects of Akt inhibitor VIII and Baicalein on human cancer cell line panel JFCR39 were also investigated, and the mean logarithm of the concentration required for 50% growth inhibition of cells (Log GI50) was determined to be −5.59 and −4.70, respectively. In addition, COMPARE analysis of the two compounds together with known PI3K inhibitors was carried out by using PI3K inhibitor ZSTK474 as a seed. Our results show that Akt inhibitor VIII displays a similar fingerprint to that of ZSTK474 (r=0.633), while Baicalein does not (r=0.126). These findings suggest the inhibition profile of Baicalein in cells is different from that of a typical PI3K inhibitor.
著者
-
YAMORI Takao
Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Resea
-
Yamori Takao
Division Of Experimental Chemotherapy Cancer Chemotherapy Center Japanese Foundation For Cancer
-
Yamazaki Kanami
Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Resea
-
Kong Dexin
Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Resea
-
Kong Dexin
Division Of Molecular Pharmacology Cancer Chemotherapy Center Japanese Foundation For Cancer Researc
-
Yamazaki Kanami
Division Of Molecular Pharmacology Cancer Chemotherapy Center Japanese Foundation For Cancer Researc
関連論文
- Discovery of Phosphatidylinositol 3-Kinase Inhibitory Compounds from the Screening Committee of Anticancer Drugs (SCADS) Library
- YM-216391, a Novel Cytotoxic Cyclic Peptide from Streptomyces nobilis : I. Fermentation, Isolation and Biological Activities
- Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107 : III. In Vitro and In Vivo Antitumor Activities
- Isolation of a Novel Gene Showing Reduced Expression in Metastatic Colorectal Carcinoma Cell Lines and Carcinomas
- Absolute Quantification of Four Isoforms of the Class I Phosphoinositide-3-kinase Catalytic Subunit by Real-Time RT-PCR(Communications to the Editor)
- Identification of Candidate Genes Determining Chemosensitivity to Anti-cancer Drugs of Gastric Cancer Cell Lines
- Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines
- Identification of JTP-70902, a p15^-inductive compound, as a novel MEK1/2 inhibitor
- ANTITUMOR EFFICACIES OF ACLACINOMYCIN A BY ORAL ADMINISTRATION
- Establishment of a Hepatocyte Cell Line Producing Growth-promoting Factors for Liver-colonizing Tumor Cells
- Anticancer and Some Biological Activities of Thiazinotrienomycin B
- Development and Characterization of a Model of Liver Metastasis Using Human Colon Cancer HCT-116 Cells(Highlighted paper selected by Editor-in-chief,Miscellaneous)
- Sesquiterpenoids and Flavonoids from the Aerial Parts of Tithonia diversifolia and Their Cytotoxic Activity
- β-Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein Tyrosine Kinases
- Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria
- Anti-tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts
- Phosphatidylinositol 3-kinase inhibitors : promising drug candidates for cancer therapy
- Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase(Pharmacology)
- Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo
- ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
- Potentiation of Bleomycin in Jurkat Cells by Fungal Pycnidione
- Development of an Immunohistochemical Protein Quantification System in Conjunction with Tissue Microarray Technology for Identifying Predictive Biomarkers for Phosphatidylinositol 3-Kinase Inhibitors
- Search for Novel Anti-tumor Agents from Ridaifens Using JFCR39, a Panel of Human Cancer Cell Lines